Effect of rosiglitazone on lung tissue inflammation, administered after the lipopolysaccharide (LPS) insult
| Treatment | G‐CSF levels pg·mg−1 | GM-CSF levels pg·mg−1 | KC levels pg·mg−1 | Neutrophilia cells×103·mg−1 |
| Vehicle/saline | 15.8±1.6 | 0.4±0.1 | 7.0±0.3 | 2832±270 |
| Vehicle/LPS | 39.8±8.2 | 3.2±0.4 | 156.5±17.5 | 8496±598 |
| Rosiglitazone/LPS | 30.0±4.7 (41) | 3.0±0.2 (7) | 136.7±7.6 (13) | 7039±516 (26) |
| Dexamethasone/LPS | 17.0±1.6 (95) | 1.0±0.1 (79) | 57.6±3.9 (66) | 8018±837 (8) |
Data are presented as mean±sem (% inhibition)
G‐CSF: granulocyte-colony stimulating factor
GM-CSF: granulocyte-macrophage-colony stimulating factor
KC: keratinocyte-derived chemokine